CDC report highlights the gaps in care of hepatitis C treatment

The prevalence of hepatitis C virus clearance was only 34% overall and even lower in individuals between 20 and 39 years of age.

Odevixibat by Ipsen for Biliary Atresia: Likelihood of Approval

Odevixibat is under clinical development by Ipsen and currently in Phase III for Biliary Atresia.

March 19, 2024

Racial, ethnic, and socioeconomic differences in air pollution-related deaths in the United States

Disparities in mortality rates by ethnicity, race, educational attainment, social vulnerability, and rurality, ascribed to differences in susceptibility and exposure to particulate matter up to

July 25, 2024

Left in limbo: When pharma halts rare disease research – Pharmaceutical Technology

When pharma companies pull out of gene therapy programmes, nonprofit organisations are taking matters into their own hands. Credit: afry_harvy via Shutterstock. The development of

July 3, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.